Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4

Using the Magellan Clay Telescope, astronomers have performed a spectroscopic study of blue straggler stars in the globular cluster NGC 3201. Results of the new study, published May 21 on the arXiv preprint server, could help us better understand the properties and chemical composition of this cluster.

First identified in the 1950s, the blue straggler stars (BSSs) are unique main-sequence (MS) stars that are brighter, bluer, and appear younger than their coeval counterparts, hence more massive than MS stars. They are positioned to the left and above the main-sequence turnoff (MSTO) in the optical color-magnitude diagram (CMD).

One of the places to look for and investigate the BSS population are (GCs)—gravitationally bound groups of stars. Due to their relatively high masses, the blue straggler stars can be used to probe the internal dynamics of GCs.

Read more | >

Published in Brain, Behavior and Immunity—is the first to suggest that a tumor-driving gene known as AEG-1 actively regulates the inflammation responsible for causing chemotherapy-induced peripheral neuropathy (CIPN), a common and painful side effect of cancer treatment. Eliminating the function of this gene using targeted therapies could become a critical strategy for managing a debilitating side effect experienced by many cancer patients.

Read more | >

Researchers have uncovered that some childhood cancers have a substantially higher number of DNA changes than previously thought, changing the way we view children’s tumors and possibly opening up new or repurposed treatment options.

Concentrating on a type of childhood kidney cancer, known as Wilms tumor, an international team genetically sequenced multiple tumors at a resolution that was previously not possible.

This collaboration included researchers at the Wellcome Sanger Institute, University of Cambridge, Princess Máxima Center for Pediatric Oncology, the Oncode Institute in the Netherlands, Great Ormond Street Hospital, and Cambridge University Hospitals NHS Foundation Trust.

Read more | >

The advancement of artificial intelligence (AI) and the study of neurobiological processes are deeply interlinked, as a deeper understanding of the former can yield valuable insight about the other, and vice versa. Recent neuroscience studies have found that mental state transitions, such as the transition from wakefulness to slow-wave sleep and then to rapid eye movement (REM) sleep, modulate temporary interactions in a class of neurons known as layer 5 pyramidal two-point neurons (TPNs), aligning them with a person’s mental states.

These are interactions between information originating from the external world, broadly referred to as the receptive field (RF1), and inputs emerging from internal states, referred to as the contextual field (CF2). Past findings suggest that RF1 and CF2 inputs are processed at two distinct sites within the neurons, known as the basal site and apical site, respectively.

Current AI algorithms employing attention mechanisms, such as transformers, perceiver and flamingo models, are inspired by the capabilities of the human brain. In their current form, however, they do not reliably emulate high-level perceptual processing and the imaginative states experienced by humans.

Read more | >

WASHINGTON — The U.S. Space Force has ordered two additional Global Positioning System satellites from Lockheed Martin. The $509.7 million contract covers GPS III satellites 21 and 22, which are part of the advanced GPS III Follow-on constellation designed to provide enhanced positioning, navigation and timing services to both civilian and military users worldwide.

Delivery of the two satellites is scheduled by 2031, according to a contract announcement May 28.

The order was placed under an existing 2018 contract that allows for up to 22 spacecraft. With this procurement, the Space Force has now exercised options for 12 satellites, bringing the total value of the contract to $4.1 billion.

Read more | >

Close to the summit of an underwater mountain west of the Mid-Atlantic Ridge, a jagged landscape of towers rises from the gloom.

Their creamy carbonate walls and columns appear ghostly blue in the light of a remotely operated vehicle sent to explore.

They range in height from tiny stacks the size of toadstools to a grand monolith standing 60 meters (nearly 200 feet) tall. This is the Lost City.

Read more | >

A new drug targeting inflammation in the brain has been shown to bolster the blood-brain barrier in mice, pioneering a potential shift in the fight against neurodegenerative diseases like Alzheimer’s.

“Finding [the drug] blocks brain inflammation and protects the blood-brain barrier was an exciting new discovery,” says pathologist Sanford Markowitz from Case Western Reserve University (CWRU).

What’s more, the researchers note that amyloid levels – the abnormally clumping proteins traditionally thought to play a role in the progress of Alzheimer’s – remained the same. This suggests the new treatment, focusing on an immune protein called 15-PGDH, targets a completely different physiological pathway than many existing medications.

Read more | >